According to Bloomberg, Swiss biotechnology company Windward Bio Group AG has raised approximately $225 million in total through its US initial public offering and concurrent private placement. The IPO was priced at the midpoint of its previously announced indicative range. This figure includes the private placement and does not represent the IPO proceeds alone.